drugset / Trial / NCT02781753

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers

NCT02781753

Phase 1 Completed 34 enrolled Tianjin SinoBiotech Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection in healthy subjects.

Timeline

Start
2016-04-07
Primary completion
2016-08-02
Completion
2017-04-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Peginterferon alfa-2a Protein / enzyme biologic 180 ug Subcutaneous
Subject interferon alfa-2b Protein / enzyme biologic 300 ug Subcutaneous
Subject interferon alfa-2b Protein / enzyme biologic 1200 ug Subcutaneous

Indications

No indication recorded.